India Daily Briefing

The RBI said it will ensure the rupee 'finds its correct level', framing the current INR as undervalued — a deliberate signal that the central bank is comfortable managing a stronger rupee path. For rate-sensitive sectors, this matters: a stronger INR compresses the import-cost advantage for consumer electronics and pharma raw-material costs. Watch for SEBI-tracked FII flow data over the next 48 hours; the RBI comment typically precedes a tightening of INR volatility windows.

Sun Pharma's board is set to consider a Non-Convertible Debenture issue of up to ₹15,000 crore on 12 October, the largest single domestic debt raise by a pharma name in recent years. This is balance-sheet expansion signalling — either a large acquisition pipeline or capex for its branded generics US push. Watch for the NCD coupon rate: if it prices above MIBOR + 80 bps, it signals even Sun's AAA-equivalent paper is feeling the yield-curve pressure from the FII selloff.

Ola Electric is launching a rights issue at ₹27 per share — a 26% discount to market price — a move that's effectively a distress signal for a company that IPO-ed above ₹76 in 2024. The deep discount structure means existing retail shareholders face meaningful dilution or must commit fresh capital at a loss-to-cost basis. For EV sector sentiment broadly, this is a cautionary flag: if the highest-profile pure-play Indian EV name needs rights-issue capital at this pace, institutional appetite for the sector re-rating will wait for actual EBITDA delivery.